Results 61 to 70 of about 5,892 (166)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

Case Reports in Nephrology and Dialysis, 2020
Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD).
Shinya Nakatani, Eiji Ishimura, Yuri Machiba, Kenta Fujimoto, Hideki Uedono, Akihiro Tsuda, Katsuhito Mori, Masanori Emoto, Masaaki Inaba   +8 more
doaj   +1 more source

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

British Journal of Pharmacology, Volume 183, Issue 16, Page 5082-5101, August 2026.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer, Paraskevi Sotiropoulou, Koussai Bouker, Dennis Svedberg, Rebekkah Hammar, Hester Bange, Per Larsson, André Mateus, Daniel R. Dietrich, Per Artursson   +9 more
wiley   +1 more source

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

, 2021
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed.
Atsushi Hosui, Takafumi Tanimoto, Toru Okahara, Kohsaku Ohnishi, Motohiro Hirao, Naoki Hiramatsu, Munehiro Ashida, Takuya Yamada, Yuhhei Wakahara, Yukihiro Kusumoto, Toshio Yamaguchi, Yuka Sueyoshi   +11 more
core   +1 more source

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

Kidney International Reports, 2017
In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal ...
Olivier Devuyst, Arlene B. Chapman, Susan E. Shoaf, Frank S. Czerwiec, Jaime D. Blais   +4 more
doaj   +1 more source

Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial

Journal of Neuroendocrinology, Volume 38, Issue 8, August 2026.
Abstract Chronic hyponatremia is associated with cognitive deficits, yet the underlying mechanisms remain elusive. A cerebral growth factor which is crucial for cognition and memory is brain‐derived neurotrophic factor (BDNF), but its role in hyponatremia has never been investigated.
Eszter Kustos‐Tóth, Julia Beck, Lucia Seeger, Sophie Monnerat, Cemile Bathelt, Julie Refardt, Mirjam Christ‐Crain   +6 more
wiley   +1 more source

Tolvaptan Improves Refractory Ascites and Overall Survival in Cirrhosis: A Meta-Analysis

Current Internal Medicine Research and Practice Surabaya Journal
Introduction: Refractory ascites is a frequent complication associated with liver cirrhosis. Tolvaptan, a V2-receptor antagonist, has shown effectiveness in improving refractory ascites.
Chetan Kalal, Harshad Joshi, Shankar Zanwar, Madhumita Premkumar   +3 more
doaj   +1 more source

SO010URINARY LITHOGENIC RISK PROFILE IN ADPKD PATIENTS TREATED WITH TOLVAPTAN

, 2020
Background and Aims Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity. In observational studies, prevalence rates of up to 36% have been
Bargagli, Matteo, Ferraro, Pietro Manuel, Huynh-Do, Uyen, Dhayat, Nasser A, Semmo, Mariam, Anderegg, Manuel, Fuster, Daniel Guido, Vogt, Bruno   +7 more
core   +1 more source

Tolvaptan Use in SIAD (Syndrome of Inappropriate Antidiuresis)

, 2021
Background: SIAD (Syndrome of Inappropriate Antidiuresis) is the commonest cause of hyponatraemia in hospital inpatients. Hyponatraemia is associated with increased length of stay and worse primary clinical outcomes.
Sushma Burri (19317760), Sathish Babu Parthasarathy (19317763)   +1 more
core  

Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial

BMC Gastroenterology, 2020
Background To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.
Jieting Tang, Yongfeng Wang, Tao Han, Qing Mao, Jun Cheng, Huiguo Ding, Jia Shang, Qin Zhang, Junqi Niu, Feng Ji, Chengwei Chen, Jidong Jia, Xiangjun Jiang, Nonghua Lv, Yueqiu Gao, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng, Yimin Mao   +19 more
doaj   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source